MedDataX Logo

Computer-based Dosage Calculation for Antibiotics

NCT ID: NCT03036826

Last Updated: 2019-12-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2019-06-30

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Adequate dosing of antiinfective therapy in critically ill patients with impaired or lost renal function or continuous renal replacement therapy is nearly impossible without measuring the drug concentration in blood samples. In many hospitals that is still not an option. The investigators aim to show, that computer based calculation can avoid over- or under-dosing.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Adequate dosing of antiinfective therapy in critically ill patients is most important to improve outcome. Patients with impaired or lost renal function or continuous renal replacement therapy are hard to calculate using drug information sheets or "lists" with recommendations. It is nearly impossible to avoid drug levels that are much to low or much to high without measuring the concentration in blood samples. Since that possibility is still not available in every clinic we aim to show, how a computer based calculation can help to find the adequate dosing.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Kidney Insufficiency Anti-Infective Agent Toxicity

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

renal replacement therapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Piperacillin/Tazobactam

Group of patients receiving Piperacillin/Tazobactam as antiinfective therapy

Piperacillin/tazobactam

Intervention Type DRUG

antiinfective therapy with Piperacillin/Tazobactam within routine care

Meropenem

Group of patients receiving Meropenem as antiinfective therapy

Meropenem

Intervention Type DRUG

antiinfective therapy with Meropenem within routine care

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Piperacillin/tazobactam

antiinfective therapy with Piperacillin/Tazobactam within routine care

Intervention Type DRUG

Meropenem

antiinfective therapy with Meropenem within routine care

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients requiring antiinfective therapy
* patients with impaired renal function or requiring continuous renal replacement therapy

Exclusion Criteria

* plasmapheresis or liver replacement therapy
* renal replacement therapy with integrated CytoSorb®-Membrane
* extracorporal live support
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital Tuebingen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stefanie Prohaska, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital Tuebingen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Tuebingen

Tübingen, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CADDy

Identifier Type: -

Identifier Source: org_study_id